Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

@article{Blackwell2010RandomizedSO,
  title={Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.},
  author={Kimberly L. Blackwell and Harold J. Burstein and Anna Maria Storniolo and Hope S Rugo and George Sledge and Maria Koehler and Catherine J. Ellis and Michelle Casey and Svetislava J. Vukelja and Joachim Bischoff and Jos{\'e} Baselga and Joyce O'Shaughnessy},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 7},
  pages={
          1124-30
        }
}
PURPOSE Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic interaction between lapatinib and trastuzumab, suggesting that dual blockade is more effective than a single agent alone. EGF104900 compared the activity of lapatinib alone or in combination with trastuzumab in patients with ErbB2-positive, trastuzumab-refractory metastatic breast cancer (MBC). PATIENTS AND METHODS Patients with ErbB2-positive MBC who experienced progression on prior trastuzumab-containing… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 424 CITATIONS

Advances in anti-HER 2 therapy in metastatic breast cancer

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Current approaches and future directions in the treatment of HER2-positive breast cancer.

VIEW 8 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2012
VIEW 10 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2011
VIEW 10 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
VIEW 8 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Targeted therapy-induced diarrhea: A review of the literature.

  • Critical reviews in oncology/hematology
  • 2014
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2010
2019

CITATION STATISTICS

  • 21 Highly Influenced Citations

  • Averaged 33 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…